Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
4(67%)
Results Posted
100%(2 trials)

Phase Distribution

Ph phase_1
2
33%
Ph phase_2
2
33%
Ph phase_3
2
33%

Phase Distribution

2

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

6

all time

Status Distribution
Active(4)
Completed(2)

Detailed Status

Recruiting3
Completed2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
4
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (33.3%)
Phase 22 (33.3%)
Phase 32 (33.3%)

Trials by Status

recruiting350%
active_not_recruiting117%
completed233%

Recent Activity

4 active trials
Showing 5 of 6
recruitingphase_3

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

NCT06958328
recruitingphase_2

NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial

NCT06821997
recruitingphase_3

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

NCT06998940
completedphase_1

Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors

NCT02631733
active_not_recruitingphase_1

Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

NCT03337087
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06958328Phase 3

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

Recruiting
NCT06821997Phase 2

NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial

Recruiting
NCT06998940Phase 3

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

Recruiting
NCT02631733Phase 1

Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors

Completed
NCT03337087Phase 1

Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

Active Not Recruiting
NCT04753216Phase 2

Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6